Inflammatory aspects of Alzheimer disease and other neurodegenerative disorders

Journal of Alzheimer's Disease

Volumn 13, Issue 4, 2008, Pages 359-369

  Schwab, Claudia ^a   McGeer, Patrick L ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Amyloid protein; Amyotrophic lateral sclerosis; Astrocytes; Microglia; Neurotoxicity; Parkinson disease; Synuclein

Indexed keywords

2,3 DIHYDRO 5 METHYL 3 (MORPHOLINOMETHYL) 6 (1 NAPHTHOYL)PYRROLO[1,2,3 DE][1,4]BENZOXAZINE; ALZHEIMER DISEASE VACCINE; AMYLOID BETA PROTEIN; AUTACOID; CANNABINOID 2 RECEPTOR BLOCKING AGENT; CANNABINOID RECEPTOR ANTAGONIST; CHEMOKINE RECEPTOR CCR2; CYCLOOXYGENASE 2 INHIBITOR; CYTOKINE; ETANERCEPT; FRACTALKINE; GAMMA INTERFERON INDUCIBLE PROTEIN 10; GROWTH FACTOR; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 1; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 1BETA; INTERLEUKIN 4; INTERLEUKIN 8; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE P38; MONOCYTE CHEMOTACTIC PROTEIN 1; NONSTEROID ANTIINFLAMMATORY AGENT; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; SOMATOMEDIN C; STAT1 PROTEIN; SYNUCLEIN; TUMOR NECROSIS FACTOR ALPHA RECEPTOR; UNINDEXED DRUG;

ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; ANTIINFLAMMATORY ACTIVITY; ASTROCYTE; CELL ACTIVATION; CELL FUNCTION; CLINICAL TRIAL; CYTOKINE RELEASE; DEGENERATIVE DISEASE; DISEASE MODEL; DRUG ADMINISTRATION ROUTE; HEALING; HUMAN; INFLAMMATION; MICROGLIA; NONHUMAN; PARASPINAL DRUG ADMINISTRATION; PARKINSON DISEASE; PHAGOCYTOSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN SECRETION; REVIEW;

EID: 47849127085     PISSN: 13872877     EISSN: None     Source Type: Journal    
DOI: 10.3233/JAD-2008-13402     Document Type: Review

References (91)

1. H. Akiyama and P.L. McGeer, Specificity of mechanisms for plaque removal after Aβ immunotherapy for Alzheimer disease, Nat Med 10 (2004), 117-118.
2. J. Apelt and R. Schliebs, Beta-amyloid-induced glial expression of both pro- and anti-inflammatory cytokines in cerebral cortex of aged transgenic Tg2576 mice with Alzheimer plaque pathology, Brain Res 894 (2001), 21-30.
3. C.R. Balistreri, C. Caruso, M.P. Grimaldi, F. Listi, S. Vasto, V. Orlando, A.M. Campagna, D. Lio, G. Candore, C.R. Balistreri, C. Caruso, M.P. Grimaldi, F. Listi, S. Vasto, V. Orlando, A.M. Campagna, D. Lio and G. Candore, CCR5 receptor: biologic and genetic implications in age-related diseases, Ann N Y Acad Sci 1100 (2007), 162-172.
4. P. Barberger-Gateau, C. Raffaitin, L. Letenneur, C. Berr, C. Tzourio, J.F. Dartigues and A. Alperovitch, Dietary patterns and risk of dementia: the Three-City cohort study, Neurology 69 (2007), 1921-1930.
5. A. Basu, J.K. Krady, J.R. Enterline and S.W. Levison, Transforming growth factor beta1 prevents IL-1beta-induced microglial activation, whereas TNFalpha- and IL-6-stimulated activation are not antagonized, Glia 40 (2002), 109-120.
6. P. Bezzi, M. Domercq, L. Brambilla, R. Galli, D. Schols, E. De Clercq, A. Vescovi, G. Bagetta, G. Kollias, J. Meldolesi and A. Volterra, CXCR4-activated astrocyte glutamate release via TNFalpha: amplification by microglia triggers neurotoxicity, Nat Neurosci 4 (2001), 702-710.
7. P. Bossu, A. Ciaramella, M.L. Moro, L. Bellincampi, S. Bernardini, G. Federici, A. Trequattrini, F. Macciardi, I. Spoletini, F. Di Iulio, C. Caltagirone and G. Spalletta, Interleukin 18 gene polymorphisms predict risk and outcome of Alzheimer's disease, J Neurol Neurosurg Psychiatry 78 (2007), 807-811.
8. O. Butovsky, A.E. Talpalar, K. Ben-Yaakov and M. Schwartz, Activation of microglia by aggregated beta-amyloid or lipopolysaccharide impairs MHC-II expression and renders them cytotoxic whereas IFN-gamma and IL-4 render them protective, Mol Cell Neurosci 29 (2005), 381-393.
9. O. Butovsky, G. Landa, G. Kunis, Y. Ziv, H. Avidan, N. Greenberg, A. Schwartz, I. Smirnov, A. Pollack, S. Jung and M. Schwartz, Induction and blockage of oligodendrogenesis by differently activated microglia in an animal model of multiple sclerosis, J Clin Invest 116 (2006), 905-915.
10. O. Butovsky, Y. Ziv, A. Schwartz, G. Landa, A.E. Talpalar, S. Pluchino, G. Martino and M. Schwartz, Microglia activated by IL-4 or IFN-gamma differentially induce neurogenesis and oligodendrogenesis from adult stem/progenitor cells, Mol Cell Neurosci 31 (2006), 149-160.
11. G. Candore, C.R. Balistreri, M.P. Grimaldi, F. Listi, S. Vasto, M. Chiappelli, F. Licastro, G. Colonna-Romano, D. Lio and C. Caruso, Polymorphisms of pro-inflammatory genes and Alzheimer's disease risk: a pharmacogenomic approach, Mech Ageing Dev 128 (2007), 67-75.
12. A.E. Cardona, E.P. Pioro, M.E. Sasse, V. Kostenko, S.M. Cardona, I.M. Dijkstra, D. Huang, G. Kidd, S. Dombrowski, R. Dutta, J.C. Lee, D.N. Cook, S. Jung, S.A. Lira, D.R. Littman, R.M. Ransohoff, A.E. Cardona, E.P. Pioro, M.E. Sasse, V. Kostenko, S.M. Cardona, I.M. Dijkstra, D. Huang, G. Kidd, S. Dombrowski, R. Dutta, J.-C. Lee, D.N. Cook, S. Jung, S.A. Lira, D.R. Littman and R.M. Ransohoff, Control of microglial neurotoxicity by the fractalkine receptor, Nature Neuroscience 9 (2006), 917-924.
13. S. Craft, Insulin resistance syndrome and Alzheimer disease: pathophysiologic mechanisms and therapeutic implications, Alzheimer Dis Assoc Disord 20 (2006), 298-301.
14. F.C. Crawford, M. Wood, S. Ferguson, V.S. Mathura, B. Faza, S. Wilson, T. Fan, B. O'Steen, G. Ait-Ghezala, R. Hayes and M.J. Mullan, Genomic analysis of response to traumatic brain injury in a mouse model of Alzheimer's disease (APPsw), Brain Res 1185 (2007), 45-58.
15. D. Davalos, J. Grutzendler, G. Yang, J.V. Kim, Y. Zuo, S. Jung, D.R. Littman, M.L. Dustin and W.B. Gan, ATP mediates rapid microglial response to local brain injury in vivo, Nat Neurosci 8 (2005), 752-758.
16. D.W. Dickson, S.C. Lee, L.A. Mattiace, S.H. Yen and C. Brosnan, Microglia and cytokines in neurological disease, with special reference to AIDS and Alzheimer's disease, Glia 7 (1993), 75-83.
17. M. Domercq, L. Brambilla, E. Pilati, J. Marchaland, A. Volterra and P. Bezzi, P2Y1 receptor-evoked glutamate exocytosis from astrocytes: control by tumor necrosis factor-alpha and prostaglandins, J Biol Chem 281 (2006), 30684-30696.
18. Y. Dong and E.N. Benveniste, Immune function of astrocytes, Glia 36 (2001), 180-190.
19. J. El Khoury, M. Toft, S.E. Hickman, T.K. Means, K. Terada, C. Geula and A.D. Luster, CCR2 deficiency impairs microglial accumulation and accelerates progression of Alzheimer-like disease, Nat Med 13 (2007), 432-438.
20. J.L. Eriksen, S.A. Sagi, T.E. Smith, S. Weggen, P. Das, D.C. McLendon, V.V. Ozols, K.W. Jessing, K.H. Zavitz, E.H. Koo and T.E. Golde, NSAIDs and enantiomers of flurbiprofen target gamma-secretase and lower Abeta 42 in vivo, J Clin Invest 112 (2003), 440-449.
21. G. Esposito, C. Scuderi, C. Savani, L. Steardo, Jr., D. De Filippis, P. Cottone, T. Iuvone, V. Cuomo and L. Steardo, Cannabidiol in vivo blunts beta-amyloid induced neuroinflammation by suppressing IL-1beta and iNOS expression, Br J Pharmacol 151 (2007), 1272-1279.
22. C. Farina, F. Aloisi, E. Meinl, C. Farina, F. Aloisi and E. Meinl, Astrocytes are active players in cerebral innate immunity, Trends Immunol 28 (2007), 138-145.
23. S. Gilman, M. Koller, R.S. Black, L. Jenkins, S.G. Griffith, N.C. Fox, L. Eisner, L. Kirby, M.B. Rovira, F. Forette and J.M. Orgogozo, Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial, Neurology 64 (2005), 1553-1562.
24. I. Glezer, A.R. Simard, S. Rivest, I. Glezer, A.R. Simard and S. Rivest, Neuroprotective role of the innate immune system by microglia, Neuroscience 147 (2007), 867-883.
25. M. Griffiths, J.W. Neal and P. Gasque, Innate immunity and protective neuroinflammation: new emphasis on the role of neuroimmune regulatory proteins, Int Rev Neurobiol 82 (2007), 29-55.
26. U.K. Hanisch and H. Kettenmann, Microglia: active sensor and versatile effector cells in the normal and pathologic brain, Nat Neurosci 10 (2007), 1387-1394.
27. M.T. Heneka and G.E. Landreth, PPARs in the brain, Biochim Biophys Acta 1771 (2007), 1031-1045.
28. M.T. Heneka, G.E. Landreth and M. Hull, Drug insight: effects mediated by peroxisome proliferator-activated receptor-gamma in CNS disorders, Nat Clin Pract Neurol 3 (2007), 496-504.
29. M. Hirohata, K. Ono, H. Naiki and M. Yamada, Non-steroidal anti-inflammatory drugs have anti-amyloidogenic effects for Alzheimer's beta-amyloid fibrils in vitro, Neuropharmacology 49 (2005), 1088-1099.
30. B.A. in't Veld, A. Ruitenberg, A. Hofman, B.H. Stricker and M.M. Breteler, Antihypertensive drugs and incidence of dementia: the Rotterdam Study, Neurobiol Aging 22 (2001), 407-412.
31. S.R. Kim, K.S. Lee, H.S. Park, S.J. Park, K.H. Min, S.M. Jin and Y.C. Lee, Involvement of IL-10 in peroxisome proliferator-activated receptor gamma-mediated antiinflammatory response in asthma, Mol Pharmacol 68 (2005), 1568-1575.
32. A. Klegeris and P.L. McGeer, Rat brain microglia and peritoneal macrophages show similar responses to respiratory burst stimulants, Journal of Neuroimmunology 53 (1994), 83-90.
33. A. Klegeris and P.L. McGeer, beta-amyloid protein enhances macrophage production of oxygen free radicals and glutamate, J Neurosci Res 49 (1997), 229-235.
34. A. Klegeris, C.J. Bissonnette and P.L. McGeer, Reduction of human monocytic cell neurotoxicity and cytokine secretion by ligands of the cannabinoid-type CB2 receptor, Br J Pharmacol 139 (2003), 775-786.
35. A. Klegeris, C.J. Bissonnette and P.L. McGeer, Modulation of human microglia and THP-1 cell toxicity by cytokines endogenous to the nervous system, Neurobiol Aging 26 (2005), 673-682.
36. A. Klegeris and P.L. McGeer, Non-steroidal anti-inflammatory drugs (NSAIDs) and other anti-inflammatory agents in the treatment of neurodegenerative disease, Curr Alzheimer Res 2 (2005), 355-365.
37. A. Klegeris, S. Pelech, B.I. Giasson, J. Maguire, H. Zhang, E.G. McGeer and P.L. McGeer, alpha-Synuclein activates stress signaling protein kinases in THP-1 cells and microglia, Neurobiol Aging 29 (2008), 739-752.
38. J. Koenigsknecht-Talboo and G.E. Landreth, Microglial phagocytosis induced by fibrillar beta-amyloid and IgGs are differentially regulated by proinflammatory cytokines, J Neurosci 25 (2005), 8240-8249.
39. J. Koenigsknecht and G. Landreth, Microglial phagocytosis of fibrillar beta-amyloid through a beta1 integrin-dependent mechanism, J Neurosci 24 (2004), 9838-9846.
40. G. Landreth, Therapeutic use of agonists of the nuclear receptor PPARgamma in Alzheimer's disease, Curr Alzheimer Res 4 (2007), 159-164.
41. L.J. Launer, Nonsteroidal Anti-Inflammatory Drug Use and the Risk for Alzheimer's Disease: Dissecting the Epidemiological Evidence, Drugs 63 (2003), 731-739.
42. C.A. Lemere, A beneficial role for IL-1 beta in Alzheimer disease?, J Clin Invest 117 (2007), 1483-1485.
43. S.M. Lucas, N.J. Rothwell, R.M. Gibson, S.-M. Lucas, N.J. Rothwell and R.M. Gibson, The role of inflammation in CNS injury and disease, British Journal of Pharmacology 147 Suppl 1 (2006), S232-240.
44. Y. Marchalant, S. Rosi and G.L. Wenk, Anti-inflammatory property of the cannabinoid agonist WIN-55212-2 in a rodent model of chronic brain inflammation, Neuroscience 144 (2007), 1516-1522.
45. E.G. McGeer and P.L. McGeer, The role of the immune system in neurodegenerative disorders, Movement Disorders 12 (1997), 855-858.
46. E.G. McGeer and P.L. McGeer, Brain inflammation in Alzheimer disease and the therapeutic implications, Curr Pharm Des 5 (1999), 821-836.
47. P.L. McGeer, E. McGeer, J. Rogers and J. Sibley, Antiinflammatory drugs and Alzheimer disease, Lancet 335 (1990), 1037.
48. P.L. McGeer and E.G. McGeer, The inflammatory response system of brain: implications for therapy of Alzheimer and other neurodegenerative diseases, Brain Res Rev 21 (1995), 195-218.
49. P.L. McGeer and E.G. McGeer, NSAIDs and Alzheimer disease: epidemiological, animal model and clinical studies, Neurobiol Aging 28 (2007), 639-647.
50. G. Mehlhorn, M. Hollborn and R. Schliebs, Induction of cytokines in glial cells surrounding cortical beta-amyloid plaques in transgenic Tg2576 mice with Alzheimer pathology, Int J Dev Neurosci 18 (2000), 423-431.
51. K.J. Min, M.S. Yang, S.U. Kim, I. Jou and E.H. Joe, Astrocytes induce hemeoxygenase-1 expression in microglia: a feasible mechanism for preventing excessive brain inflammation, J Neurosci 26 (2006), 1880-1887.
52. L. Minghetti, M.A. Ajmone-Cat, M.A. De Berardinis and R. De Simone, Microglial activation in chronic neurodegenerative diseases: roles of apoptotic neurons and chronic stimulation, Brain Res Rev 48 (2005), 251-256.
53. T. Mizuno, J. Kawanokuchi, K. Numata and A. Suzumura, Production and neuroprotective functions of fractalkine in the central nervous system, Brain Res 979 (2003), 65-70.
54. D. Morgan, Modulation of microglial activation state following passive immunization in amyloid depositing transgenic mice, Neurochem Int 49 (2006), 190-194.
55. R.G. Nagele, M.R. D'Andrea, H. Lee, V. Venkataraman and H.Y. Wang, Astrocytes accumulate A beta 42 and give rise to astrocytic amyloid plaques in Alzheimer disease brains, Brain Res 971 (2003), 197-209.
56. K. Nakajima, Y. Tohyama, S. Maeda, S. Kohsaka, T. Kurihara, K. Nakajima, Y. Tohyama, S. Maeda, S. Kohsaka and T. Kurihara, Neuronal regulation by which microglia enhance the production of neurotrophic factors for GABAergic, catecholaminergic, and cholinergic neurons, Neurochem Int 50 (2007), 807-820.
57. H. Neumann and K. Takahashi, Essential role of the microglial triggering receptor expressed on myeloid cells-2 (TREM2) for central nervous tissue immune homeostasis, J Neuroimmunol 184 (2007), 92-99.
58. J.A. Nicoll, D. Wilkinson, C. Holmes, P. Steart, H. Markham and R.O. Weller, Neuropathology of human Alzheimer disease after immunization with amyloid-beta peptide: a case report, Nat Med 9 (2003), 448-452.
59. A. Nimmerjahn, F. Kirchhoff and F. Helmchen, Resting microglial cells are highly dynamic surveillants of brain parenchyma in vivo, Science 308 (2005), 1314-1318.
60. Z. Pei, H. Pang, L. Qian, S. Yang, T. Wang, W. Zhang, X. Wu, S. Dallas, B. Wilson, J.M. Reece, D.S. Miller, J.S. Hong and M.L. Block, MAC1 mediates LPS-induced production of superoxide by microglia: the role of pattern recognition receptors in dopaminergic neurotoxicity, Glia 55 (2007), 1362-1373.
61. M. Persson, M. Brantefjord, E. Hansson and L. Ronnback, Lipopolysaccharide increases microglial GLT-1 expression and glutamate uptake capacity in vitro by a mechanism dependent on TNF-alpha, Glia 51 (2005), 111-120.
62. R. Pihlaja, J. Koistinaho, T. Malm, H. Sikkila, S. Vainio and M. Koistinaho, Transplanted astrocytes internalize deposited beta-amyloid peptides in a transgenic mouse model of Alzheimer's disease, Glia 56 (2007), 154-163.
63. L. Qian, M.L. Block, S.J. Wei, C.F. Lin, J. Reece, H. Pang, B. Wilson, J.S. Hong and P.M. Flood, Interleukin-10 protects lipopolysaccharide-induced neurotoxicity in primary midbrain cultures by inhibiting the function of NADPH oxidase, J Pharmacol Exp Ther 319 (2006), 44-52.
64. L. Qian, J.S. Hong and P.M. Flood, Role of microglia in inflammation-mediated degeneration of dopaminergic neurons: neuroprotective effect of interleukin 10, J Neural Transm Suppl (2006), 367-371.
65. L. Qin, X. Wu, M.L. Block, Y. Liu, G.R. Breese, J.S. Hong, D.J. Knapp and F.T. Crews, Systemic LPS causes chronic neuroinflammation and progressive neurodegeneration, Glia 55 (2007), 453-462.
66. E.M. Ramos, M.T. Lin, E.B. Larson, I. Maezawa, L.H. Tseng, K.L. Edwards, G.D. Schellenberg, J.A. Hansen, W.A. Kukull and L.W. Jin, Tumor necrosis factor alpha and interleukin 10 promoter region polymorphisms and risk of late-onset Alzheimer disease, Arch Neurol 63 (2006), 1165-1169.
67. S. Ray, M. Britschgi, C. Herbert, Y. Takeda-Uchimura, A. Boxer, K. Blennow, L.F. Friedman, D.R. Galasko, M. Jutel, A. Karydas, J.A. Kaye, J. Leszek, B.L. Miller, L. Minthon, J.F. Quinn, G.D. Rabinovici, W.H. Robinson, M.N. Sabbagh, Y.T. So, D.L. Sparks, M. Tabaton, J. Tinklenberg, J.A. Yesavage, R. Tibshirani and T. Wyss-Coray, Classification and prediction of clinical Alzheimer's diagnosis based on plasma signaling proteins, Nat Med 13 (2007), 1359-1362.
68. G. Razay, A. Vreugdenhil and G. Wilcock, The metabolic syndrome and Alzheimer disease, Arch Neurol 64 (2007), 93-96.
69. J. Rogers, N.R. Cooper, S. Webster, J. Schultz, P.L. McGeer, S.D. Styren, W.H. Civin, L. Brachova, B. Bradt, P. Ward et al., Complement activation by beta-amyloid in Alzheimer disease, Proc Natl Acad Sci USA 89 (1992), 10016-10020.
70. D. Rossi, L. Brambilla, C.F. Valori, A. Crugnola, G. Giaccone, R. Capobianco, M. Mangieri, A.E. Kingston, A. Bloc, P. Bezzi and A. Volterra, Defective tumor necrosis factor-alpha-dependent control of astrocyte glutamate release in a transgenic mouse model of Alzheimer disease, J Biol Chem 280 (2005), 42088-42096.
71. M. Sastre, T. Klockgether, M.T. Heneka, M. Sastre, T. Klockgether and M.T. Heneka, Contribution of inflammatory processes to Alzheimer's disease: molecular mechanisms, Int J Dev Neurosci 24 (2006), 167-176.
72. S.S. Shaftel, S. Kyrkanides, J.A. Olschowka, J.N. Miller, R.E. Johnson and M.K. O'Banion, Sustained hippocampal IL-1 beta overexpression mediates chronic neuroinflammation and ameliorates Alzheimer plaque pathology, J Clin Invest 117 (2007), 1595-1604.
73. I. Shaked, D. Tchoresh, R. Gersner, G. Meiri, S. Mordechai, X. Xiao, R.P. Hart, M. Schwartz, I. Shaked, D. Tchoresh, R. Gersner, G. Meiri, S. Mordechai, X. Xiao, R.P. Hart and M. Schwartz, Protective autoimmunity: interferon-gamma enables microglia to remove glutamate without evoking inflammatory mediators, J Neurochem 92 (2005), 997-1009.
74. A. Simi, N. Tsakiri, P. Wang and N.J. Rothwell, Interleukin-1 and inflammatory neurodegeneration, Biochem Soc Trans 35 (2007), 1122-1126.
75. W.L. Smith, R.M. Garavito and D.L. DeWitt, Prostaglandin endoperoxide H synthases (cyclooxygenases)-1 and -2, J Biol Chem 271 (1996), 33157-33160.
76. W.J. Streit, Microglial senescence: does the brain's immune system have an expiration date?, Trends Neurosci 29 (2006), 506-510.
77. C.A. Szekely, T. Town and P.P. Zandi, NSAIDs for the chemoprevention of Alzheimer's disease, Subcell Biochem 42 (2007), 229-248.
78. N. Tanuma, H. Sakuma, A. Sasaki, Y. Matsumoto, N. Tanuma and H. Sakuma, Chemokine expression by astrocytes plays a role in microglia/macrophage activation and subsequent neurodegeneration in secondary progressive multiple sclerosis, Acta Neuropathologica 112 (2006), 195-204.
79. E. Tobinick, H. Gross, A. Weinberger and H. Cohen, TNF-alpha modulation for treatment of Alzheimer's disease: a 6-month pilot study, Med Gen Med 8 (2006), 25.
80. N.P. Turrin and S. Rivest, Tumor necrosis factor alpha but not interleukin 1 beta mediates neuroprotection in response to acute nitric oxide excitotoxicity, J Neurosci 26 (2006), 143-151.
81. M. Vanhanen, K. Koivisto, L. Moilanen, E.L. Helkala, T. Hanninen, H. Soininen, K. Kervinen, Y.A. Kesaniemi, M. Laakso and J. Kuusisto, Association of metabolic syndrome with Alzheimer disease: a population-based study, Neurology 67 (2006), 843-847.
82. S. Vesce, D. Rossi, L. Brambilla, A. Volterra, S. Vesce, D. Rossi, L. Brambilla and A. Volterra, Glutamate release from astrocytes in physiological conditions and in neurodegenerative disorders characterized by neuroinflammation, Int Rev Neurobiol 82 (2007), 57-71.
83. R. von Bernhardi, G. Ramirez, R. Toro and J. Eugenin, Proinflammatory conditions promote neuronal damage mediated by Amyloid Precursor Protein and decrease its phagocytosis and degradation by microglial cells in culture, Neurobiol Dis 26 (2007), 153-164.
84. D.G. Walker, J. Link, L.F. Lue, J.E. Dalsing-Hernandez and B.E. Boyes, Gene expression changes by amyloid beta peptide-stimulated human postmortem brain microglia identify activation of multiple inflammatory processes, J Leukoc Biol 79 (2006), 596-610.
85. G.S. Watson, B.A. Cholerton, M.A. Reger, L.D. Baker, S.R. Plymate, S. Asthana, M.A. Fishel, J.J. Kulstad, P.S. Green, D.G. Cook, S.E. Kahn, M.L. Keeling and S. Craft, Preserved cognition in patients with early Alzheimer disease and amnestic mild cognitive impairment during treatment with rosiglitazone: a preliminary study, Am J Geriatr Psychiatry 13 (2005), 950-958.
86. S. Webster, L.F. Lue, L. Brachova, A.J. Tenner, P.L. McGeer, K. Terai, D.G. Walker, B. Bradt, N.R. Cooper and J. Rogers, Molecular and cellular characterization of the membrane attack complex, C5b-9, in Alzheimer's disease, Neurobiol Aging 18 (1997), 415-421.
87. S.D. Webster, A.J. Tenner, T.L. Poulos, D.H. Cribbs, S.D. Webster, A.J. Tenner, T.L. Poulos and D.H. Cribbs, The mouse C1q A-chain sequence alters beta-amyloid-induced complement activation, Neurobiol Aging 20 (1999), 297-304.
88. B. Wilkinson, J. Koenigsknecht-Talboo, C. Grommes, C.Y. Lee and G. Landreth, Fibrillar beta-amyloid-stimulated intracellular signaling cascades require Vav for induction of respiratory burst and phagocytosis in monocytes and microglia, J Biol Chem 281 (2006), 20842-20850.
89. M.S. Yang, K.A. Ji, S.B. Jeon, B.K. Jin, S.U. Kim, I. Jou and E. Joe, Interleukin-13 enhances cyclooxygenase-2 expression in activated rat brain microglia: implications for death of activated microglia, J Immunol 177 (2006), 1323-1329.
90. S.L. Yates, L.H. Burgess, J. Kocsis-Angle, J.M. Antal, M.D. Dority, P.B. Embury, A.M. Piotrkowski and K.R. Brunden, Amyloid beta and amylin fibrils induce increases in proinflammatory cytokine and chemokine production by THP-1 cells and murine microglia, J Neurochem 74 (2000), 1017-1025.
91. Y. Yoshiyama, M. Higuchi, B. Zhang, S.M. Huang, N. Iwata, T.C. Saido, J. Maeda, T. Suhara, J.Q. Trojanowski and V.M. Lee, Synapse loss and microglial activation precede tangles in a P301S tauopathy mouse model, Neuron 53 (2007), 337-351.